✦ LIBER ✦

Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: An analysis of the CERTIFY study

✍ Scribed by S.M. Schellong; H.-E. Gerlach; U. Tebbe; S. Haas; N. Melzer; C. Abletshauser; C. Sieder; P. Bramlage; H. Riess; R. Bauersachs

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Certoparin versus unfractionated heparin

✍ Ulrich Tebbe; Sebastian M. Schellong; Sylvia Haas; Horst Eberhard Gerlach; Claud 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 405 KB

A randomized, double-blind study of cert

✍ H. RIESS; S. HAAS; U. TEBBE; H.-E. GERLACH; C. ABLETSHAUSER; C. SIEDER; S. ROSSO 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

Benefits versus risks of pharmacological

✍ Moshe Vardi, Michal Steinberg, Michal Haran, Shai Cohen 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 298 KB

AOS13 Denosumab versus zoledronic acid f

✍ A.T. Stopeck; G. Richardson; S. Siena; A. Lipton; J. Brown; K. Fizazi; D. Henry; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 41 KB